Kirkwood JM - Search Results

1

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY. Ortiz A, et al. Among authors: kirkwood jm. Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001. Cancer Cell. 2019. PMID: 30645975 Free PMC article.

2

Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells.

Jost LM, Kirkwood JM, Whiteside TL. Jost LM, et al. Among authors: kirkwood jm. J Immunol Methods. 1992 Mar 4;147(2):153-65. doi: 10.1016/s0022-1759(12)80003-2. J Immunol Methods. 1992. PMID: 1548398

3

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.

Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM. Ernstoff MS, et al. Among authors: kirkwood jm. Cancer Res. 1992 Feb 15;52(4):851-6. Cancer Res. 1992. PMID: 1737346 Clinical Trial.

4

Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.

Sedlmayr P, Rabinowich H, Elder EM, Ernstoff MS, Kirkwood JM, Herberman RB, Whiteside TL. Sedlmayr P, et al. Among authors: kirkwood jm. J Immunother (1991). 1991 Oct;10(5):336-46. doi: 10.1097/00002371-199110000-00005. J Immunother (1991). 1991. PMID: 1790141

5

Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model.

Levy SM, Herberman RB, Lee J, Whiteside T, Kirkwood J, McFeeley S. Levy SM, et al. Nat Immun Cell Growth Regul. 1990;9(5):313-24. Nat Immun Cell Growth Regul. 1990. PMID: 2077396

6

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.

Ernstoff MS, Nair S, Bahnson RR, Miketic LM, Banner B, Gooding W, Day R, Whiteside T, Hakala T, Kirkwood JM. Ernstoff MS, et al. Among authors: kirkwood jm. J Clin Oncol. 1990 Oct;8(10):1637-49. doi: 10.1200/JCO.1990.8.10.1637. J Clin Oncol. 1990. PMID: 2120392

7

Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients.

Levy SM, Herberman RB, Whiteside T, Sanzo K, Lee J, Kirkwood J. Levy SM, et al. Psychosom Med. 1990 Jan-Feb;52(1):73-85. doi: 10.1097/00006842-199001000-00006. Psychosom Med. 1990. PMID: 2305024

8

Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.

Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL. Weidmann E, et al. Among authors: kirkwood jm. Cancer Res. 1993 Oct 15;53(20):4745-9. Cancer Res. 1993. PMID: 8402652

9

Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates.

Vlock DR, Andersen J, Kalish LA, Johnson JT, Kirkwood JM, Whiteside T, Herberman RB, Adams GS, Oken MM, Haselow RE. Vlock DR, et al. Among authors: kirkwood jm. J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):433-42. doi: 10.1097/00002371-199611000-00008. J Immunother Emphasis Tumor Immunol. 1996. PMID: 9041463 Clinical Trial.

10

Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.

Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL. Kirkwood JM, et al. J Immunother. 1997 Mar;20(2):146-57. doi: 10.1097/00002371-199703000-00007. J Immunother. 1997. PMID: 9087387 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

609 results

Search Page

Filters